KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EBITDA: 2010-2025

Historic EBITDA for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $76.5 million.

  • Emergent BioSolutions' EBITDA rose 18.60% to $76.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.5 million, marking a year-over-year increase of 182.87%. This contributed to the annual value of -$108.7 million for FY2024, which is 85.04% up from last year.
  • As of Q3 2025, Emergent BioSolutions' EBITDA stood at $76.5 million, which was up 4,681.25% from $1.6 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year EBITDA high stood at $286.8 million for Q4 2021, and its period low was -$292.9 million during Q2 2023.
  • In the last 3 years, Emergent BioSolutions' EBITDA had a median value of -$9.5 million in 2024 and averaged -$64.3 million.
  • As far as peak fluctuations go, Emergent BioSolutions' EBITDA surged by 894.83% in 2021, and later tumbled by 2,239.13% in 2023.
  • Emergent BioSolutions' EBITDA (Quarterly) stood at $286.8 million in 2021, then crashed by 119.28% to -$55.3 million in 2022, then rose by 20.80% to -$43.8 million in 2023, then spiked by 78.31% to -$9.5 million in 2024, then increased by 18.60% to $76.5 million in 2025.
  • Its EBITDA stands at $76.5 million for Q3 2025, versus $1.6 million for Q2 2025 and $49.9 million for Q1 2025.